Following demonstration of monotherapy efficacy, a number of NSCLC clinical trials are now exploring anti-PD-1/PD-L1 antibodies in combination with chemotherapy [14, 15] or with molecularly targeted therapies [16, 17]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.